STOCKS TELEGRAPH

Tag: Sonoma stock

  • Sonoma (SNOA) Boosts Market Presence With UK Regulatory Success

    Sonoma (SNOA) Boosts Market Presence With UK Regulatory Success

    Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) experienced a sharp increase after a significant regulatory victory in the UK. SNOA stock was up 63.94% at $3.82 as of the most recent market check. Following the company’s news that its range of acne treatments based on hypochlorous acid had been successfully registered with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), investor confidence skyrocketed.

    Strategic Retail Launch in Europe

    In the UK, a large health and beauty store will sell the approved products—an acne toner and a balancing serum—under its own name. More than 1,200 retailers nationwide are now scheduled to carry these products. This action represents a significant turning point in Sonoma Pharmaceuticals’ larger European distribution plan and their first significant foray into the UK consumer skincare sector.

    Dermatological Care Innovation

    With its all-natural hypochlorous acid and Sonoma’s exclusive Microcyn® technology, the acne product range provides a mild yet efficient substitute for conventional treatments like benzoyl peroxide and alcohol-based formulations. The company’s dedication to using safe, non-toxic chemicals is in line with the growing demand from customers for skincare products that are safer.

    Broadening Regulatory Footprint in the UK

    This most recent milestone comes after Sonoma’s production facilities and five of its medical goods—including skin exfoliants, hydrogel for wound care, scar management products, and wound irrigation solutions—were previously registered by the MHRA. These approvals emphasize the efficacy and safety of SNOA’s formulations, supported by clinical evidence suggesting that hypochlorous acid may successfully manage small skin lesions and irritations without hurting healthy tissue.

    Positioned for European Growth

    Sonoma Pharmaceuticals is well-positioned to increase its presence in the UK and larger European markets thanks to these regulatory achievements. The company views the UK as an important market for its dermatological and wound care products. These latest registrations’ success demonstrates SNOA’s dedication to international healthcare innovation and its potential for significant regional market expansion.

  • Sonoma Pharmaceuticals (SNOA) Gains In Pre-Hour Trading

    Sonoma Pharmaceuticals (SNOA) Gains In Pre-Hour Trading

    Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares were rising 11.90% to $3.95 as of this morning’s last pre-market check. SNOA has made a number of encouraging announcements in the last week, which have led to this notable increase in stock value.

    New MHRA Registrations Signal the UK Market’s Growth

    The Medicines & Healthcare medicines Regulatory Agency (MHRA) recently granted Sonoma Pharmaceuticals permission to register its production facility and five important medicines in the UK. The recently authorized goods include a skin exfoliator, wound hydrogel, a variety of scar management solutions, and a wound irrigation solution based on hypochlorous acid.

    With this registration, Sonoma will be able to reach a wider audience and increase its market share in the UK by introducing its cutting-edge Microcyn-based products. The business was excited about the prospects for expansion this clearance offers in the dermatology and wound care industries.

    Adopting EU Medical Device Regulations with Success

    Sonoma Pharmaceuticals has accomplished a significant regulatory milestone in Europe in addition to registering in the UK. Four of the company’s products were successfully converted to conform to the Medical Device Regulation (MDR) of the European Union. These consist of Pediacyn for atopic dermatitis, Microdacyn60 Wound Care, Microdacyn60 Hydrogel, and the scar gel Epicyn.

    Strict requirements for the performance and safety of medical devices are mandated by the MDR, which took the place of the old Medical Device Directive in 2017. A noteworthy accomplishment is Sonoma’s early adherence to these new rules, which guarantees that its goods will satisfy all safety and legal criteria before the December 2028 date.

    Evidence of Regulatory Readiness and Product Safety

    Sonoma’s dedication to product safety and regulatory vigilance is demonstrated by the successful registration and classification of its products as Class IIb medical devices in Europe. The company’s solid clinical data and capacity to adjust to changing international requirements are clearly demonstrated by the shift to MDR compliance.

  • Sonoma (SNOA) Stock Rallies After Reverse-Split Trading Begins

    Sonoma (SNOA) Stock Rallies After Reverse-Split Trading Begins

    The value Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares are increasing significantly today, indicating that the market has responded favorably to the company’s switch to a reverse-split. SNOA stock surged 9.66% to $3.49 as of the most recent check.

    Specifics of the Reverse Stock Split

    Previously this week, Sonoma Pharmaceuticals announced that it will reverse its stock split one-for-20. The split was planned to take effect on August 29, 2024, at 5:00 PM EDT. The company’s shareholders approved the reverse split during the annual meetings on August 14–23, 2024, which led to this decision.

    The Board of Directors authorized the split and set the ratio on August 23, 2024. In order to preserve Sonoma’s listing status on the Nasdaq Capital Market, a calculated strategic maneuver was made with the reverse stock split. Sonoma hopes to increase investor interest, boost stakeholder confidence, and open up new business growth options by keeping its Nasdaq listing.

    Every twenty shares of Sonoma’s common stock will convert into one new share, without altering the par value per share. Consequently, the total number of shares will reduce from approximately 20 million to around one million.

    Operational Developments

    Operationally, Sonoma Pharmaceuticals has expanded the claims for its Nanocyn Disinfectant and Sanitizer after the Australian Therapeutic Goods Administration (TGA) granted an extension. Utilizing Sonoma’s proprietary Microcyn technology, Nanocyn is manufactured for MicroSafe and has received additional approvals for its ability to effectively combat Clostridium difficile (C. diff.) and Candida auris (C. auris) in less than ten minutes.

    Nanocyn has previously been approved by the Australian Register of Therapeutic Goods for use against a variety of germs, viruses, influenza A, and SARS-CoV-2. Nanocyn is already recognized by the Environmental Protection Agency (EPA) of the United States as a disinfectant that effectively fights diseases such as MRSA, Salmonella, mpox, SARS-CoV-2, and others.

    Strategic Impact

    By tackling a variety of dangerous pathogens, these additional TGA approvals strengthen Sonoma Pharmaceuticals’ leadership in broad-use disinfection technology and reaffirm its dedication to strict safety regulations.

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.

  • Pre-Market Cues: 30 Stocks Roaring for Change On December 14th

    Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter products.

    Livent Corporation (NYSE: LTHM) shares are trading up 3.6% at $17.0 at the time of writing. Company’s 52-week ranged between $3.95 to $17.53. Analysts have a consensus price target of $16.50.

    Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares are trading down -5.45% at $2.95 at the time of writing after declaring offering of common stock. Company’s 52-week ranged between $1.03 to $5.31.

    NextDecade Corporation (NEXT) is down more than -7.25% at $3.2 in pre-market hours Monday December 14, 2020. The stock had jumped over 38.00% to $3.45 in the last trading session.

    FAT Brands Inc. (FAT) tumbled over -4.06% at $7.57 in pre-market trading today following the announcement from the company that it has entered into an agreement to combine with Fog Cutter Capital Group Inc. (FCCG), the Company’s controlling stockholder.

    Recro Pharma Inc. (REPH) stock soared 3.21% to $3.05 in the pre-market trading. The most recent rating by Stephens, on October 17, 2019, is an Overweight.

    Ampio Pharmaceuticals Inc. (AMPE) stock moved up 3.33 percent to $1.55 in the pre-market trading.

    ReTo Eco-Solutions Inc. (RETO), a Building Materials company, rose about 3.91% at $0.665 in pre-market trading Monday.

    Yiren Digital Ltd. (YRD) lost over -5.36% at $3.0 in pre-market trading Monday December 14, 2020. The firm recently announced that it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion™.

    Before the trading started on December 14, 2020, Sabre Corporation (SABR) is up 3.46% to reach $11.35. It has been trading in a 52-week range of $3.30 to $23.25.

    NantHealth Inc. (NH) is up more than 1.74% at $3.5 in pre-market hours Monday December 14, 2020. The company recently presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. The stock had jumped over 22.42% to $3.44 in the last trading session.

    Torchlight Energy Resources Inc. (TRCH) stock soared 15.79% to $0.88 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    NIO Limited (NYSE: NIO) shares are trading down -6.38% at $39.3 at the time of writing following the announcement of pricing of offering of 68,000,000 American Depositary Shares. Company’s 52-week ranged between $2.11 to $57.20. Analysts have a consensus price target of $59.

    Lightbridge Corporation (LTBR) is down more than -2.4% at $3.66 in pre-market hours Monday December 14, 2020. The stock had jumped over 12.28% to $3.75 in the last trading session.

    Foresight Autonomous Holdings Ltd. (FRSX) stock moved up 2.31 percent to $1.77 in the pre-market trading after its affiliate, Rail Vision Ltd., has received an order from Knorr-Bremse Systeme für Schienenfahrzeuge GmbH, an affiliate of Knorr-Bremse AG (Frankfurt: KBX), for two samples of their light rail vehicle (LRV) system.

    Before the trading started on December 14, 2020, Hennessy Capital Acquisition Corp. IV (HCAC) is up 2.32% to reach $20.75. It has been trading in a 52-week range of $9.21 to $22.43.

    Inseego Corp. (INSG) stock soared 10.36% to $15.18 in the pre-market trading after reporting that the company is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. The most recent rating by ROTH Capital, on August 06, 2020, is a Neutral.

    Mechel PAO (MTL) is down more than -3.66% at $1.84 in pre-market hours Monday December 14, 2020. The stock had jumped over 11.05% to $1.91 in the last trading session.

    JinkoSolar Holding Co. Ltd. (NYSE: JKS) shares are trading up 3.58% at $54.9 at the time of writing after declaring an update to 2020 annual general meeting agenda. Company’s 52-week ranged between $11.42 to $90.20. Analysts have a consensus price target of $55.

    Before the trading started on December 14, 2020, CureVac N.V. (CVAC) is up 6.7% to reach $125.99. It has been trading in a 52-week range of $36.15 to $151.80.

    Xeris Pharmaceuticals Inc. (XERS) grew over 2.84% at $4.7 in pre-market trading today after recent proclamation from company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Teligent Inc. (NASDAQ: TLGT) shares are trading up 85.54% at $1.17 at the time of writing. Company’s 52-week ranged between $0.46 to $6.46. Analysts have a consensus price target of $2.

    Marathon Patent Group Inc. (MARA) gained over 15.58% at $5.49 in pre-market trading Monday December 14, 2020. The firm recently announced a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners.

    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 4.64% at $0.53 at the time of writing after reporting that it has received approval to transfer the listing of its common shares to the Nasdaq Capital Market. Company’s 52-week ranged between $0.14 to $3.88.

    Neos Therapeutics Inc. (NEOS) tumbled over -5.61% at $0.6532 in pre-market trading today. The company and Aytu BioScience, Inc. (AYTU) recently declared that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.

    Arbutus Biopharma Corporation (ABUS), a Biotechnology company, rose about 6.14% at $4.15 in pre-market trading Monday. The healthcare firm lately declared additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

    Greenwich LifeSciences Inc. (GLSI) lost over -16.07% at $47.0 in pre-market trading Monday December 14, 2020 following the publication of a second poster for the GP2 Phase III clinical trial design for recurring breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in a virtual format.

    Veru Inc. (VERU) is up more than 19.12% at $7.57 in pre-market hours Monday December 14, 2020 following the company revealed positive Phase 2 clinical trial results for enobosarm, for the treatment of endocrine and chemotherapy resistant ER+/HER2- metastatic breast cancer. The stock had jumped over 6.45% to $6.36 in the last trading session.

    NanoVibronix Inc. (NAOV) stock plunged -6.36% to $1.03 in the pre-market trading after reporting that it has expanded and replaced its original distribution agreement with Ultra Pain Products, Inc..

    SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares are trading down -11.23% at $7.43 at the time of writing following the pricing of $16.2 million registered direct offering. Company’s 52-week ranged between $1.46 to $19.38.

  • Sonoma Pharmaceuticals (SNOA) announced its financial results for the 2nd quarter and 6 months

    Sonoma Pharmaceuticals (SNOA) announced its financial results for the 2nd quarter and 6 months

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a multinational healthcare giant, has released financial results for its second fiscal quarter and six months ended September 30, 2020, manufacturing and supplying stabilized hypochlorous acid (HOCl) drugs for a wide variety of uses, including wound treatment, eye care, nasal care, oral care, and dermatological disorders. It also announced that, because of factual irregularities, it had to restate its first-quarter financial statements for the quarter ended June 30, 2020. The key highlights for the 6 months, ended September 30, 2020

    Sonoma recently completed the transition from Petaluma, CA to Woodstock, GA during the second fiscal year All manufacturing is now achieved at the state-of-the-art Sonoma plant in Zapopan, Mexico. As a result of this reorganization, Sonoma plans to see a continuous decrease in both overhead and the cost of products sold.

    Joint research was conducted in the Journal of Hospital Infection by the University of Hong Kong and Queen Mary Hospital using Dermodacyn Disinfecting solution, a medical-grade solution manufactured by Sonoma and marketed in Hong Kong by Sonoma partner Microderm Technologies Limited.   The study found that Dermodacyn Disinfecting solution significantly decreased the viability of SARS-CoV-2 against other laboratory and domestic disinfectants that are widely used.

    As the company works with its multinational network of retail partners to increase the number of goods and markets where such products are sold, Sonoma’s international market has continued to demonstrate strength. Sonoma, for instance, partnered with its affiliate Te Arai BioFarma to launch two new nasal and oral care brands in Australia and New Zealand, as previously announced on September 9, 2020.

    With an average rise in sales and a decline in operational expenses, Sonoma’s operating efficiency tends to grow quarter after quarter. Although the COVID-19 pandemic has created a daunting global climate, the versatility of Sonoma’s product lines and global markets served has not only proved to separate Sonoma from geographical downturns, but in some countries, the company’s anti-viral and anti-bacterial drugs have seen elevated demand.